PDE5 Expression and Function in the Lower Urinary Tract: A Critical Review

data concerning PDE5 expression and function in these lower urinary tract

[1]  P. Cuevas,et al.  Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. , 2012, The journal of sexual medicine.

[2]  J. Wyndaele,et al.  Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein‐induced hyperactivity of these nerves , 2012, BJU international.

[3]  M. Carini,et al.  A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. , 2012, The journal of sexual medicine.

[4]  O. Koca,et al.  Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms , 2012, Andrologia.

[5]  A. Kanai,et al.  Mechanisms of action of botulinum neurotoxins, β3‐adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI‐RS 2011 , 2012, Neurourology and urodynamics.

[6]  A. Seftel,et al.  Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. , 2012, American journal of physiology. Endocrinology and metabolism.

[7]  M. Carini,et al.  Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. , 2011, The journal of sexual medicine.

[8]  R. Middendorff,et al.  Cyclic GMP signaling in rat urinary bladder, prostate, and epididymis: tissue-specific changes with aging and in response to Leydig cell depletion. , 2011, Reproduction.

[9]  Ji-Hong Liu,et al.  An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia. , 2011, Asian journal of andrology.

[10]  S. Oger,et al.  Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats. , 2011, European urology.

[11]  D. Behr-Roussel,et al.  Nitric oxide/cyclic guanosine monophosphate signalling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat. , 2010, European urology.

[12]  G. Lin,et al.  Prominent expression of phosphodiesterase 5 in striated muscle of the rat urethra and levator ani. , 2010, The Journal of urology.

[13]  G. Untergasser,et al.  Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia. , 2010, Endocrinology.

[14]  P. Validire,et al.  Signalling pathways involved in sildenafil‐induced relaxation of human bladder dome smooth muscle , 2010, British journal of pharmacology.

[15]  K. Kim,et al.  Open-label, Intermittent Dose, Prospective Study Evaluating the Effects of Tadalafil on Lower Urinary Tract Symptoms and Erectile Function in Patients with Benign Prostatic Hyperplasia: Continuation and Durability of Effects. , 2010, International neurourology journal.

[16]  D. Moon,et al.  Relaxation Effect of Phosphodiesterase-5 Inhibitor on the Animal Bladder and Prostatic Urethra: in vitro and in vivo Study , 2010, Urologia Internationalis.

[17]  C. Roehrborn,et al.  Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. , 2010, The Journal of urology.

[18]  G. Vannelli,et al.  Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. , 2010, The journal of sexual medicine.

[19]  K. Andersson,et al.  Vardenafil‐induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder , 2009, BJU international.

[20]  G. Lin,et al.  Lack of direct androgen regulation of PDE5 expression. , 2009, Biochemical and biophysical research communications.

[21]  J. Ashton-Miller,et al.  Stress urinary incontinence: relative importance of urethral support and urethral closure pressure. , 2008, The Journal of urology.

[22]  C. Stief,et al.  A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. , 2008, European urology.

[23]  K. Kohri,et al.  Role of nitric oxide/cyclic GMP pathway in regulating spontaneous excitations in detrusor smooth muscle of the guinea‐pig bladder , 2008, Neurourology and urodynamics.

[24]  C. Stief,et al.  Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. , 2008, Urology.

[25]  C. Roehrborn,et al.  Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. , 2007, The Journal of urology.

[26]  M. Carini,et al.  Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. , 2007, The Journal of urology.

[27]  M. Yoo,et al.  Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia , 2007, International journal of urology : official journal of the Japanese Urological Association.

[28]  M. Carini,et al.  Characterization and functional role of androgen-dependent PDE5 activity in the bladder. , 2007, Endocrinology.

[29]  K. McVary,et al.  Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. , 2007, The Journal of urology.

[30]  C. Fowler,et al.  Results of double-blind placebo-controlled crossover study of sildenafil citrate (Viagra) in women suffering from obstructed voiding or retention associated with the primary disorder of sphincter relaxation (Fowler's Syndrome). , 2007, European urology.

[31]  P. Sandner,et al.  Pre‐clinical evidence for the use of phosphodiesterase‐5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms , 2006, BJU international.

[32]  K. Andersson,et al.  Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects , 2006, BJU international.

[33]  J. Mulhall,et al.  Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. , 2006, The journal of sexual medicine.

[34]  C. Stief,et al.  Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. , 2006, European urology.

[35]  G. Vannelli,et al.  Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. , 2005, European urology.

[36]  G. Lin,et al.  Cyclic nucleotide signaling in cavernous smooth muscle. , 2005, The journal of sexual medicine.

[37]  M. Giorgi,et al.  Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. , 2004, Endocrinology.

[38]  M. Drake,et al.  The actions of sodium nitroprusside and the phosphodiesterase inhibitor dipyridamole on phasic activity in the isolated guinea‐pig bladder , 2004, BJU international.

[39]  T. Lue,et al.  Cyclic nucleotide signaling in vascular and cavernous smooth muscle: aging-related changes , 2004 .

[40]  G. Lin,et al.  Isolation of two isoforms of phosphodiesterase 5 from rat penis , 2003, International Journal of Impotence Research.

[41]  A. Ramage,et al.  An investigation of the effects of zaprinast, a PDE inhibitor, on the nitrergic control of the urethra in anaesthetized female rats , 2002, British journal of pharmacology.

[42]  U. Jonas,et al.  Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. , 2001, The Journal of urology.

[43]  A. Garcia-Pascual,et al.  Nitrergic relaxation in urethral smooth muscle: involvement of potassium channels and alternative redox forms of NO , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.

[44]  T. Lue,et al.  Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. , 2000, Biochemical and biophysical research communications.

[45]  K. Fujishige,et al.  Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases. , 1999, European journal of biochemistry.

[46]  S. Phillips,et al.  Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). , 1998, Biochemical and biophysical research communications.

[47]  C. Stief,et al.  Cyclic Nucleotide Phosphodiesterase (PDE) Isoenzymes in the Human Detrusor Smooth Muscle: II. Effect of Various PDE Inhibitors on Smooth Muscle Tone and Cyclic Nucleotide Levels In Vitro , 1998 .

[48]  S. Ballard,et al.  Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. , 1998, The Journal of urology.

[49]  L. Baskin,et al.  Smooth and striated muscle development in the intrinsic urethral sphincter. , 1997, The Journal of urology.

[50]  P. Longhurst,et al.  The role of cyclic nucleotides in guinea‐pig bladder contractility , 1997, British journal of pharmacology.